^
NOTCH1 mutation
|
Prolymphocytic Leukemia
|
NOTCH1 mutation
|
Prolymphocytic Leukemia
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
JAK3 mutation
|
Prolymphocytic Leukemia
|
JAK3 mutation
|
Prolymphocytic Leukemia
|
venetoclax + ruxolitinib Sensitive: C3 – Early Trials
|
venetoclax + ruxolitinib Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
Prolymphocytic Leukemia
|
CDKN2A deletion
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
STAT5B N642H
|
Prolymphocytic Leukemia
|
STAT5B N642H
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
TCL1A rearrangement
|
Prolymphocytic Leukemia
|
TCL1A rearrangement
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
RAD50 Y625
|
Prolymphocytic Leukemia
|
RAD50 Y625
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
ATM D2721N
|
Prolymphocytic Leukemia
|
ATM D2721N
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
PAK4 deletion
|
Prolymphocytic Leukemia
|
PAK4 deletion
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
BRAF V600E
|
Prolymphocytic Leukemia
|
BRAF V600E
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
BRAF V600E
|
Prolymphocytic Leukemia
|
BRAF V600E
|
Prolymphocytic Leukemia
|
venetoclax Resistant: C4 – Case Studies
|
venetoclax Resistant: C4 – Case Studies
|
BRAF V600E
|
Prolymphocytic Leukemia
|
BRAF V600E
|
Prolymphocytic Leukemia
|
dasatinib Resistant: C4 – Case Studies
|
dasatinib Resistant: C4 – Case Studies
|
BRAF V600E
|
Prolymphocytic Leukemia
|
BRAF V600E
|
Prolymphocytic Leukemia
|
vemurafenib Sensitive: C4 – Case Studies
|
vemurafenib Sensitive: C4 – Case Studies
|
